Allopurinol
The active substance of Milurit is allopurinol. Allopurinol belongs to a group of medicines called enzyme inhibitors. These substances are effective in controlling the rate of certain changes in the body.
Milurit is used long-term to prevent gout and may be used in other conditions related to an excess of uric acid in the body, such as kidney stones and other kidney diseases, as well as when the patient is receiving treatment for cancer or has enzyme function disorders.
Before starting treatment with Milurit, you should discuss it with your doctor.
Special caution and close medical supervision may be necessary:
In case of doubt as to whether any of the above situations apply, you should consult a doctor or pharmacist.
Severe skin reactions (hypersensitivity syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported during treatment with allopurinol.
Often, the rash can involve ulcers of the mouth, throat, nose, genitals, and conjunctivitis (redness and swelling of the eyes). These potentially life-threatening severe skin reactions are often preceded by flu-like symptoms such as fever, headache, and body aches.
The rash may progress to generalized blisters and skin peeling.
These severe skin reactions may occur more frequently in people of Chinese, Thai, or Korean origin. Chronic kidney disease may also increase the risk in these patients.
Do not restart treatment with Milurit.
Early in the treatment with Milurit, an acute gout attack can be expected. Therefore, the doctor may recommend prophylactic use of an appropriate anti-inflammatory medicine or colchicine for at least a month.
To monitor the safety and efficacy of treatment with Milurit, the doctor may order one or more laboratory tests. You should have these tests done and show the results to your doctor.
If the patient has been diagnosed with cancer or Lesch-Nyhan syndrome, the amount of uric acid in the urine may increase. To prevent this, you should drink enough fluids to properly dilute the urine.
If the patient has kidney stones, the stones in the kidneys will decrease in size during treatment and may move into the urinary tract.
Children and adolescents under 15 years of age should not take Milurit, except in cases of certain cancers (especially leukemia) or in the treatment of certain enzyme disorders, such as Lesch-Nyhan syndrome.
You should tell your doctor about any medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
The following medicines are of particular importance:
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take. This includes medicines sold without a prescription, including herbal medicines. This is necessary because Milurit may affect the action of other medicines. Other medicines may also affect the action of Milurit.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult a doctor or pharmacist before taking this medicine.
Pregnancy
The safety of using Milurit during pregnancy is not well documented.
Milurit should only be used during pregnancy if there is no safer alternative and the disease itself poses a risk to the mother or the unborn child.
Breastfeeding
Allopurinol is excreted in the breast milk of nursing mothers. Allopurinol is not recommended during breastfeeding.
Drowsiness, dizziness, or coordination disorders may occur. If such symptoms occur, you should not drive or operate machinery.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
This medicine should always be taken exactly as prescribed by your doctor. If you are unsure, you should consult your doctor or pharmacist.
Milurit should be taken once a day after a meal. As long as you are taking this medicine, you should drink plenty of fluids (2-3 liters per day). If the daily dose exceeds 300 mg and the patient experiences gastrointestinal side effects such as nausea and vomiting (see section 4), the doctor may prescribe allopurinol in divided doses to reduce these effects.
Dosing should always be determined individually by the doctor.
The doctor usually starts treatment with a low dose of allopurinol (e.g., 100 mg/day) to reduce the risk of side effects. If necessary, the dose will be increased.
Recommended maintenance doses are:
100 to 200 mg per day in mild conditions, 300 to 600 mg per day in moderate conditions, and 700 to 900 mg per day in severe conditions.
If the dose needs to be determined in mg/kg of body weight, a dose of 2 to 10 mg/kg of body weight per day should be used.
Early in the treatment, the doctor may prescribe an anti-inflammatory medicine or colchicine to be taken for at least a month to prevent gout attacks.
In children under 15 years of age, Milurit is used in doses of 10 to 20 mg/kg of body weight per day, up to a maximum dose of 400 mg per day in 3 divided doses. The use of Milurit in children is rarely indicated, except in cases of cancer (especially leukemia) and certain enzyme disorders, such as Lesch-Nyhan syndrome.
The doctor will recommend the smallest dose of Milurit that will best control the symptoms.
If the patient is dialyzed 2 or 3 times a week, the doctor may recommend a dose of 300 or 400 mg to be taken after dialysis.
In case of kidney disease, the doctor may monitor kidney function, especially if the patient is also taking diuretics (especially thiazide diuretics).
The doctor may recommend taking smaller doses. Periodic liver function tests may be necessary, especially at the start of treatment.
Treatment of conditions with increased uric acid turnover(e.g., cancer, enzyme function disorders)
It is recommended that the increased uric acid level be corrected before starting cytotoxic therapy. It is important to ensure adequate fluid intake.
In case of skin reactions, you should immediatelystop taking allopurinol. After mild skin reactions have resolved, you can restart taking the medicine in a small dose (e.g., 50 mg/day) after careful consideration of the risks. Then, the dose can be gradually increased while monitoring for skin reactions and other potential side effects. In case of a rash relapse, you should permanentlydiscontinue the medicine, considering the possibility of severe skin reactions (see section 4 Possible side effects).
In case of taking a higher dose of Milurit than recommended, or if you think a child has swallowed the tablets, you should contact a doctor or immediately go to the hospital emergency department. You should bring this leaflet, the remaining tablets, and the packaging of the medicine so that the doctor knows which tablets were taken.
The most common symptoms of overdose are nausea, vomiting, diarrhea, or dizziness.
Until medical help is provided, you should ensure a large intake of fluids.
In case of missing a dose, you should take it as soon as you remember. However, if it is almost time for the next dose, you should skip the missed dose. You should not take a double dose to make up for the missed dose. You should continue treatment as prescribed by your doctor.
The duration of treatment is determined by the doctor.
You should not stop taking Milurit without first consulting your doctor, unless you experience allergic reactions or other severe side effects (see section 4).
In case of any further doubts about the use of this medicine, you should consult a doctor or pharmacist.
Like all medicines, Milurit can cause side effects, although not everybody gets them.
Side effects related to the use of Milurit are rare in the treated patient population and are usually mild. The frequency of side effects increases in cases of concomitant kidney and/or liver disease.
Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (see section 2).
Uncommon(may affect up to 1 in 100 people):
You should not take more tablets than prescribed by your doctor.
Rare(may affect up to 1 in 1,000 people)
Very rare(may affect up to 1 in 10,000 people):
Frequency not known(cannot be estimated from the available data)
Other possible side effects
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Frequency not known(cannot be estimated from the available data):
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: +48 (22) 49 21 301
fax: +48 (22) 49 21 309
website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
There are no special storage precautions.
Do not use this medicine after the expiry date (month, year) stated on the packaging.
The expiry date refers to the last day of the stated month.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of Milurit is allopurinol.
200 mg tablets: each tablet contains 200 mg of allopurinol.
The other ingredients are: microcrystalline cellulose, sodium carboxymethylcellulose (type A), gelatin, colloidal anhydrous silica, magnesium stearate.
Appearance:
200 mg tablets: white or grayish, oval tablets, with "E354" engraved on one side and a snap line on the other side. The tablet can be divided into equal doses.
Packaging
30 tablets in a brown glass bottle with a plastic cap and a desiccant plug, in a cardboard box.
Egis Gyógyszergyár Zrt.
1106 Budapest, Keresztúri út 30-38.
Hungary
Egis Gyógyszergyár Zrt.
9900 Körmend, Mátyás király utca 65.
Hungary
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Hungarian marketing authorization number, in the country of export: OGYI-T-3431/31
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.